NCT05184816: A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Leptomeningeal Disease
Additional Notes: Breast cancer patients are only eligible for phase 1a of the study

Comments are closed.

Up ↑